

San Bernardino County COVID-19 Therapeutics Update

Issue 10 | April 22, 2022

“The secret to change is to focus all of your energy, not on fighting the old, but on building the new”

-Socrates

PAXLOVID ADDITIONAL PACKAGING

As of April 14, 2022, the U.S. Food and Drug Administration (FDA) revised the Emergency Use Authorization for Paxlovid to authorize an additional dose pack presentation with appropriate dosing for patients with moderate renal impairment. Paxlovid will be available in two package presentations.

- Standard packaging that is within distribution: 300 mg nirmatrelvir; 100 mg ritonavir. Each carton contains 30 tablets divided in 5 daily-dose blister cards. Each blister card contains 4 nirmatrelvir tablets (150 mg each) and 2 ritonavir tablets (100 mg each).
- New packaging will begin being distributed later this month: 150 mg nirmatrelvir; 100 mg ritonavir. Each carton will now contain 20 tablets divided in 5 daily-dose blister cards. Each blisters contains 2 nirmatrelvir tablets (150 mg each) and 2 ritonavir tablets (100 mg each).

For more information please refer to [Provider Fact Sheet](#), [Letter of Authorization](#) and [Healthcare Provider Letter](#).



COVID-19 Response

Our job is to create a county in which those who reside and invest can prosper and achieve well-being.

www.SBCOVID19.com

UTILIZING THE THERAPEUTIC TRACKER

The [therapeutic locator](#) is a great resource to locate facilities and pharmacies with various COVID-19 Therapeutics. Using this tracker will help providers find a facility that can fill a prescription for a patient, in the event you do not currently have on-hand inventory. The accuracy of the therapeutic tracker is contingent upon HPOP inventory. Please ensure you are entering your current inventory daily.



KEEPING EXPIRIED MONOCLONAL ANTIBODIES

On April 13, 2022, the FDA and the Department of Health and Human Services Office issued a statement that the shelf-life of Bamlanivimab and/or Etesevimab (BAM-ETE) is being evaluated and an update regarding shelf life extension is planned for early May 2022. Until further data regarding this extension is released, all BAM-ETE vials may be retained regardless of the expiration date. This recommendation is for all properly stored and unopened vials of BAM-ETE as detailed in the letter of authorization and factsheet.

BAM- ETE is not currently authorized for use in any U.S. region. However, this recommendation is in the event that future SARS-CoV-2 variants may be susceptible to this medication.

If an undamaged product absolutely needs to be returned, follow the instructions from the manufacturer:

- For **BAM/ETE**, see The Lilly Return Goods Procedure [here](#).

- For **REGEN-COV**, call (844) 734-6643.
- Reconstituted (diluted) product **SHOULD NOT** be returned and should be treated as waste per your facility's SOP.

HRSA Uninsured Program Update

Beginning on April 5, 2022, HRSA COVID-19 Coverage Assistance Fund will be ending. Regardless of funding or insurance status, providers are **NOT** authorized to charge for the administration or other costs related to COVID-19 therapeutics. California's Department of Health Care Services currently covers COVID-19-related services including all medically necessary care, at no cost to the patient for up to 12 months or the end of the public health emergency, whichever comes first.

- **It does remain the responsibility of the patient to apply for the COVID-19 Uninsured Group prior to receiving treatments.**
- **Medi-Cal Program is still available for low-income California residents and will cover treatment services and medically necessary care. For information, please review the resources below.**
 - [COVID-19 Uninsured Group Program](#)
 - [FAQ COVID-19 Uninsured Group PDF](#)
 - [Medi-Cal Health Insurance Enrollment](#)
 - [DHCS Keeping Medi-Cal Beneficiaries Covered](#)

San Bernardino County now has an email account dedicated to COVID-19 Therapeutics! Please forward any inquiries to SBCOVID19Therapeutics@dph.sbcounty.gov.

